News
MRNA
108.85
+0.89%
0.96
Moderna Stock Jumps On Collaboration With OpenAI: What's Going On?
Moderna Inc announced an ongoing collaboration with OpenAI. The company and Microsoft Corp.-backed OpenAI share a vision of AI’s transformative potential in the future of business and healthcare. Moderna says it has reached more than 80% internal adoption of OpenAI's ChatGPT.
Benzinga · 10h ago
Moderna and OpenAI in pact to fast-track drug development
Healthcare Tech Moderna and OpenAI in pact to fast-track drug development. About 3,000 employees at Massachusetts-based biotech Moderna will have access to AI firm's ChatGPT Enterprise. Moderna has partnered with AI firm OpenAI to deploy the technology across its business.
Seeking Alpha · 10h ago
MODERNA AND OPENAI COLLABORATE TO ADVANCE MRNA MEDICINE
Reuters · 11h ago
At Moderna, OpenAI's GPTs Are Changing Almost Everything
Biotechnology company Moderna is expected to announce a partnership with artificial-intelligence heavyweight OpenAI. The deal aims to use AI to automate nearly every business process at the biotechnology company. Some 3,000 Moderna employees will have access to OpenAI's ChatGPT Enterprise as part of the deal. Moderna's only commercial product is a vaccine.
The Wall Street Journal · 13h ago
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Moderna Inc. Is set to clash with Pfizer Inc. And BioNTech SE in a pivotal London patent trial concerning the development of COVID-19 vaccines. Moderna alleges patent infringement by its competitors in utilizing the mRNA platform crucial to vaccine development. The trial is slated to take place in London.
Benzinga · 1d ago
Moderna Investors Should Beware Patent-Dispute Fallout
Moderna is facing a patent dispute over its use of lipid nanoparticles technology without proper licensing or compensation. The company's cancer vaccine showed promising results in a clinical trial. Moderna's stock rose after positive results from its cancer vaccine trial. I believe the company's defense, citing an obscure law, is unlikely to hold up in court. The outcome could result in significant damages.
Seeking Alpha · 1d ago
S&P 500 stocks with biggest estimated EPS declines for Q1
Seeking Alpha · 1d ago
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer vs Moderna battle over COVID vaccine patents begins in UK. Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19. Moderna says Pfizer copied its technology before the pandemic began.
Reuters · 1d ago
Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?
NASDAQ · 1d ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
NASDAQ · 1d ago
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates. Life science real estate investment trust posts rise in funds from operations for first quarter. Occupancy of operating properties in North America as of March 31 stood at 94.6%. Company operates and develops life science laboratories, offices across North America.
Reuters · 2d ago
Moderna stock closes in green after eight sessions of losses
Seeking Alpha · 2d ago
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
NASDAQ · 2d ago
MRNA March 2025 Options Begin Trading
NASDAQ · 2d ago
Health Care Sector Update for 04/22/2024: KURA, VAXX, MRNA, XLV, IBB
NASDAQ · 2d ago
Benjamin Graham Detailed Fundamental Analysis - MRNA
NASDAQ · 2d ago
Moderna Announced Contract With Brazil's Ministry Of Health (Ministério Da Saúde) To Supply Its mRNA Covid-19 Vaccine, Following Brazilian Health Regulatory Agency's Approval Of Its Updated Covid-19 Vaccine In March 2024
Benzinga · 2d ago
MODERNA: UNDER CONTRACT, 12.5 MLN DOSES OF MODERNA'S MRNA COVID-19 VACCINE ARE ANTICIPATED FOR DELIVERY IN Q2 OF 2024
Reuters · 2d ago
Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares
Moderna, Inc. Has a price-to-sales ratio of 5.7x. The company's revenues fell 64% in the last year. Its revenue growth is forecast to fall into negative territory over the next three years. Moderna's P/S ratio may be low because of the company's poor revenue growth.
Simply Wall St · 2d ago
Weekly Report: what happened at MRNA last week (0415-0419)?
Weekly Report · 2d ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.